000 01969nam a2200313Ia 4500
001 288234
003 OCoLC
005 20160527201727.0
008 070810s2007 vau b 000 0 eng d
010 _a2007033206
020 _a9781570185762 (alk. paper)
020 _a157018576X (alk. paper)
035 _a(OCoLC)237292273
040 _aPUCPR
049 _acicg
050 0 0 _aKF 2915 .P4
_bP495 2007
245 0 0 _aPharmaceutical law
_bregulation of research, development, and marketing
_ceditor-in-chief, Michael E. Clark.
260 _aArlington, Va
_bBureau of National Affairs
_cc2007.
300 _axlvi, 853 p.
_c26 cm.
500 _a"American Bar Association, Health Law Section"
504 _aIncludes bibliographical references and index.
505 0 _aStatutory and regulatory controls for drug development -- Key federal agencies regulating pharmaceuticals -- Federal regulation of advertising, promotion, and distribution practices -- Potential liability for drug companies, health care providers and insurers: off-label prescribing and internet advertising -- Federal regulation of clinical research -- Avoiding fraud and abuse penalties and sanctions -- Regulation of privacy under hipaa and other privacy laws -- Federal sentencing guidelines and compliance measures -- The FDA approval process for new drugs -- State regulatory schemes for pharmaceuticals and related issues -- Antitrust and intellectual law issues for pharmaceutical companies -- Securities law issues and disclosure considerations for pharmaceutical companies.
650 0 _aPharmacy
_xLaw and legislation
_zUnited States.
_2Local
_9150493
650 0 _aDrug development
_zUnited States.
_2Local
_988797
650 0 _aPharmaceutical Industry
_zUnited States.
_2Local
_9150476
650 0 _aDrugs
_xLaw and legislation
_zUnited States.
_2Local
_988821
700 1 _aClark, Michael E.
_d1956-
_2Local
_973972
710 2 _aAmerican Bar Association.
_bHealth Law Section.
_2Local
_952025
999 _c208468
_d208468